Product Description
Guanabenz belongs to the general class of medicines called antihypertensives. It is used to treat high blood pressure (hypertension). (Sourced from: https://www.mayoclinic.org/drugs-supplements/guanabenz-oral-route/description/drg-20064106)
Mechanisms of Action: ADRA2A Agonist, ADRA2B Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Germany | New Zealand | Peru | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: Amsterdam UMC
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Other|Liver Diseases, Alcoholic|Fatty Liver, Alcoholic|Hepatitis, Alcoholic|Non-alcoholic Steatohepatitis|Amyotrophic Lateral Sclerosis
Phase 1: Multiple Sclerosis, Relapsing-Remitting
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02443103 |
IUCRO-0506 | N/A |
Terminated |
Bone Cancer |
2016-06-08 |
2025-08-27 |
Primary Endpoints|Treatments |
|
NCT02423083 |
15-N-0117 | P1 |
Terminated |
Multiple Sclerosis, Relapsing-Remitting |
2017-10-30 |
2019-03-20 |
Treatments |
|
2024-518834-95-02 |
2024-518834-95-02 | P2 |
Not yet recruiting |
Other |
2029-11-30 |
|||
2023-503320-89-00 |
VWM1 | P2 |
Active, not recruiting |
Other |
2025-12-01 |
2025-05-02 |
Treatments |
|
2017-001438-25 |
2017-001438-25 | P2 |
Unknown status |
Other |
2024-04-21 |
2025-05-06 |
Treatments|Trial Status |
|
NCT05084404 |
YCU-21001 | P2 |
Unknown status |
Hepatitis, Alcoholic|Liver Diseases, Alcoholic|Fatty Liver, Alcoholic|Non-alcoholic Steatohepatitis |
2023-02-28 |
2024-09-04 |
Primary Endpoints|Treatments|Trial Status |
|
2014-005367-32 |
PROMISE | P2 |
Completed |
Amyotrophic Lateral Sclerosis |
2018-10-28 |
2025-05-06 |
Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
04/04/2023 |
News Article |
Antihypertensive Drugs Market size to grow by USD 5.87 billion from 2021 to 2026, Driven by the availability of a wide range of drugs - Technavio |